The stock has a 36-month beta value of 0.91. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RXRX is 215.35M, and at present, short sellers hold a 23.39% of that float. On August 13, 2024, the average trading volume of RXRX was 5.83M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
RXRX) stock’s latest price update
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) has experienced a decline in its stock price by -4.13 compared to its previous closing price of 6.29. However, the company has seen a fall of -10.93% in its stock price over the last five trading days. fool.com reported 2024-08-11 that On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve the new-drug discovery process with artificial intelligence.
RXRX’s Market Performance
RXRX’s stock has fallen by -10.93% in the past week, with a monthly drop of -27.87% and a quarterly drop of -29.88%. The volatility ratio for the week is 8.46% while the volatility levels for the last 30 days are 8.15% for Recursion Pharmaceuticals Inc The simple moving average for the past 20 days is -21.20% for RXRX’s stock, with a -32.71% simple moving average for the past 200 days.
Analysts’ Opinion of RXRX
Many brokerage firms have already submitted their reports for RXRX stocks, with Morgan Stanley repeating the rating for RXRX by listing it as a “Equal-Weight.” The predicted price for RXRX in the upcoming period, according to Morgan Stanley is $8 based on the research report published on May 22, 2023 of the previous year 2023.
Needham, on the other hand, stated in their research note that they expect to see RXRX reach a price target of $17. The rating they have provided for RXRX stocks is “Buy” according to the report published on March 16th, 2023.
KeyBanc Capital Markets gave a rating of “Overweight” to RXRX, setting the target price at $20 in the report published on September 16th of the previous year.
RXRX Trading at -25.74% from the 50-Day Moving Average
After a stumble in the market that brought RXRX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -61.69% of loss for the given period.
Volatility was left at 8.15%, however, over the last 30 days, the volatility rate increased by 8.46%, as shares sank -26.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.02% lower at present.
During the last 5 trading sessions, RXRX fell by -10.93%, which changed the moving average for the period of 200-days by -0.50% in comparison to the 20-day moving average, which settled at $7.54. In addition, Recursion Pharmaceuticals Inc saw -38.84% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RXRX starting from Gibson Christopher, who proposed sale 20,000 shares at the price of $6.50 back on Aug 08 ’24. After this action, Gibson Christopher now owns shares of Recursion Pharmaceuticals Inc, valued at $130,000 using the latest closing price.
Gibson Christopher, the Chief Executive Officer of Recursion Pharmaceuticals Inc, sale 20,000 shares at $6.50 during a trade that took place back on Aug 08 ’24, which means that Gibson Christopher is holding 758,738 shares at $130,000 based on the most recent closing price.
Stock Fundamentals for RXRX
Current profitability levels for the company are sitting at:
- -8.24 for the present operating margin
- -0.26 for the gross margin
The net margin for Recursion Pharmaceuticals Inc stands at -7.62. The total capital return value is set at -0.59. Equity return is now at value -71.18, with -51.98 for asset returns.
Based on Recursion Pharmaceuticals Inc (RXRX), the company’s capital structure generated 0.06 points at debt to capital in total, while cash flow to debt ratio is standing at -8.36. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -5712.15.
Currently, EBITDA for the company is -317.6 million with net debt to EBITDA at 1.07. When we switch over and look at the enterprise to sales, we see a ratio of 25.86. The receivables turnover for the company is 19.48for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.07.
Conclusion
To sum up, Recursion Pharmaceuticals Inc (RXRX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
